1. PubMed Central
As a service to our authors, Molecular Oncology will deposit to PubMed Central (PMC) author manuscripts on behalf of authors reporting NIH funded research. The service will help authors comply with the National Institutes of Health (NIH) revised “Public Access Policy,” effective April 7, 2008. The NIH's revised policy requires that NIH‐funded authors submit to PubMed Central (PMC), or have submitted on their behalf, their peer‐reviewed author manuscripts, to appear on PMC no later than 12 months after final publication.
Elsevier will send to PMC the final peer‐reviewed manuscript, which was accepted for publication and sent to Elsevier's production department, and this includes any author‐agreed changes made in response to peer‐review comments. Elsevier, on behalf of FEBS, will authorize the author manuscript's public access posting 12 months after final publication. Following the deposit by Elsevier, authors will receive further communications from the NIH with respect to the submission.
Authors are also welcome to post their accepted author manuscript on their personal or institutional web site. Please note that consistent with Elsevier's author agreement, authors should not post manuscripts directly to PMC or other third party sites.
2. Sponsored access
Molecular Oncology offers authors the option to sponsor non‐subscriber access to individual articles. The charge for article sponsorship is $3000. This charge is necessary to offset publishing costs – from managing article submission and peer review, to typesetting, tagging and indexing of articles, hosting articles on dedicated servers, supporting sales and marketing costs to ensure global dissemination via ScienceDirect, and permanently preserving the published journal article. The fee excludes taxes and other potential author fees such as color charges, which are additional.
Authors can only select this option after receiving notification that their article has been accepted for publication. This prevents a potential conflict of interest where a journal would have a financial incentive to accept an article. Authors who have had their article accepted and who wish to sponsor their article should complete and submit the order form.
3. Open access
Free access to recent archive (delayed access): Molecular Oncology provides non‐subscriber access to articles after a pre‐defined period of time (12 months) has elapsed following final publication.
4. PubMed title abbreviation
The correct title abbreviation, used by PubMed for Molecular Oncology, is Mol. Oncol. Authors are advised to take this correct abbreviation into account when citing the journal in order to avoid citations being missed or hard to retrieve. Citations to articles in press can be made using the unique DOI number for each article.
(2008), NIH funded authors and PubMed coverage, Molecular Oncology, 2, doi: 10.1016/j.molonc.2008.10.001.